Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06331455

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer

Sponsor: Marc de Perrot

Conditions Lung Cancer Patients Non-small Cell Lung Cancer (NSCLC)

Interventions Durvalumab Non-ablative oligofractionated radiation (NORT)

Updated 4 times since 2024 Last updated: Jul 18, 2024 Started: May 22, 2024 Primary completion: Dec 31, 2025 Completion: Apr 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer Patients and Non-small Cell Lung Cancer (NSCLC) and is currently actively recruiting participants. Marc de Perrot leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marc de Perrot
Ozmosis Research Inc.

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada